Author Archives for
AEON Biopharma to Host Key Opinion Leader Webinar on Past, Present, and Potential Future Treatments for Migraine on February 24th
Live event scheduled for Friday, February 24th at 11:00 am Eastern Time IRVINE, Calif., February 14, 2023 – AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused…
AEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong Pharmaceutical
IRVINE, Calif., February 10, 2023 – AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple…
AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million
IRVINE, Calif., January 10, 2023 – AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple…
A Transformation of the Healthcare Experience
Empowering patients, enabling specialists, and driving innovation in the health and wellness industry.
AEON Biopharma and Priveterra Acquisition Corp. Announce Filing of S-4 Registration Statement for Proposed Business Combination
IRVINE, Calif., December 27, 2022 – AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company developing a proprietary botulinum toxin for the treatment of multiple debilitating medical conditions,…
AEON Biopharma Completes Enrollment in Phase 2 Trial
of ABP-450 for Preventive Treatment of Episodic Migrain – Topline data expected to be announced in 2H 2023 – – Topline data from the Company’s Phase 2 trial in preventive…
Overview: Proposed Merger Agreement with Priveterra Acquisition Corp. (Nasdaq: PMGM)
Download the full presentation
AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology
AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology – Positive topline data…